Clinical Trials Logo

Hepatitis C Viral Infection clinical trials

View clinical trials related to Hepatitis C Viral Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT02716428 Completed - Chronic Hepatitis C Clinical Trials

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Start date: May 2016
Phase: Phase 2
Study type: Interventional

Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in treatment-naïve participants with genotype 1b hepatitis C virus (HCV) infection.

NCT ID: NCT02593162 Completed - Chronic Hepatitis C Clinical Trials

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

Start date: October 2015
Phase: Phase 2
Study type: Interventional

Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis C virus (HCV) infection.

NCT ID: NCT02478229 Terminated - Clinical trials for Hepatitis C Viral Infection

Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

Start date: June 2015
Phase: Phase 3
Study type: Interventional

The study is a single centre, single arm, open-label, proof of concept study enrolling 20 adult primary liver transplant recipients with genotype 1 HCV infection. Subjects will receive Sofosbuvir (SOF) and Ledipasvir (LDV) starting at time of liver transplantation (OLT) and continues for 12 weeks. Subjects will be receive 24 week post-treatment follow up.